Get started

MRNA

$MRNA$MRNA Bullish falling wedge Resistance: 65.16 Support: 47.56 Buy: $56.40 Stop loss: $50.99 Limit sell: $63.90 Notes: Still feel sketch about their "Secondary offering" it tells shareholders that they are going to take a giant ass pile of cash and set it on fire. However, as will all offerings... someone has to make money so you can decide if it is worth a longer term hold. Does the 3x run up justify its price. They just got caught saying they had "positive results" on a 45 person study and then redacted those comments.
NASDAQ:MRNA
by IMF_Trading
[NVAX] Sliding Back to $40, Collapse if It Breaks ThroughI missed this guy when I jumped on MRNA and INO earlier this week. Just trying to pin this one down a bit, coronavirus stocks are wild and fun :). For FOMO stocks, typical support and resistance horizontal lines aren't as predictive and you should instead look to the Volume Profile. Support should be right around the POC, which is $40. It should slide down to that and hang a bit before breaking through and crashing down. May bounce back up too but seems unlikely. All indicators are lining up at the start of a downward channel and signaling a short move too. June market crash is probably gonna move this more than anything as retail tries to secure their tiny profits or stem their massive losses.
NASDAQ:NVAXShort
by ProfitHarvest
8
Moderna (MRNA)+300%, is it still possible to earn money or not? Many people are interested in the question, will the shares of Moderna (MRNA) go even higher or not? After all, not so long ago, they were able to show growth of more than 300% in a few months! I will tell you this - if you prefer systematic trading and open your trades on signals, it is not clear at the moment (so we chose a neutral or observational idea). But an even more important question is how to detect the same signal when it appears again on other stocks or instruments? The answer is simple-keep track of those who practice and actually trade and earn money on the exchange. I recommend that you subscribe to several channels of those whose words do not differ from their deeds, as I did in my time - this is the best tool for selecting stocks that are right for you. Well, for everyone who likes to take risks and shorten the action before it gives a clear signal, I will tell you that according to our system of 4 screens, it is "forbidden" to short in the long run.
NASDAQ:MRNA
by ivan_gold_star_
[MRNA] Attempting to Pin Down Hyperbolic FOMO... Gonna Tank?Nothing too serious here, just an observer on this one. One of my biggest regrets, I pumped money into INO instead of MRNA when they were both cheap when the smart play was covering the field. Noob move... alas, there's always another stock to chase. Anyway, here's a decent stock architecture for anyone playing this. Basically I'm just hoping it dips super low temporarily to $30-$40 on a market crash or something and would absolutely pick this up, otherwise it's long gone outside my playing field. Who knows, maybe it'll collapse anyway simply without enough news to keep it pumped, we'll see. Vaccine news will pump and dump these stocks for the next 18 months lol so great segment to jump into if you're swing trading. Probably not the best idea to buy now. Vaccine (and revenue!) is 12-18 months away. Hype alone won't hold these prices up.
NASDAQ:MRNAShort
by ProfitHarvest
$MRNA FOMO run? Lazy Elliott ForecastI know the news about Moderna is hype right now but technicals are showing a bearish divergence from the RSI. Based on the "Lazy Elliott" Forecast, if you're going to assume this plot to be an impulse wave, wave 3 from this perspective might be complete already. One way to verify is if the price closes below the 161.8% level, it might signal the start of wave 4. Assuming further that wave 4 might be a "simple" correction compared to wave 2 (applying rule of alternation because 2 looks "complex", correct me if I'm wrong) Watch if the price doesn't go beyond the 100% level support. Be open for an extended wave 3 if the hype continues (261.8% above)
NASDAQ:MRNA
by thetradingcomedy
Moderna's Phase 2, $90 Target InevitableFirst off, please don't take anything I say seriously or as financial advice. As always, this is on opinion based basis. Moderna's Covid19 vaccine for mRNA-1273 is reaching Phase 2 clinical trails by the FDA which is further ahead than most of its small competitors and bio-pharmaceutical corporations. As always, you see the big giant crushing the small one. This news is expected to have a surge in buy signals and once it passes the $70 threshold quite soon, it will lead to a $90 short being the next actual target. That's right it can go that high, and who would be surprised?
NASDAQ:MRNAShort
by gamer456148
1
Staying AFLOAT - 05/13/20 RECAPHi traders, Quite a good trading day on Wednesday, I ended up around BE for the day but I felt generally in good control. One small improvement could've been made in early exit of my first trade. My Trades: 1) ALC - SHORT @56.94, I made a small mistake of not exiting earlier as ALC wasn't reacting at all to the market going down again. -1.06 2) MRNA - LONG @63.58, with the market not supporting longs at that time, I played a bit safe and took half off early. +1.27% *In my ID trades, I risk 1% of the account per trade and go for 2% (2:1 RRR ). Sometimes I adapt a little bit as you can see in the trades' description.* Total PnL for the day: +0.21% Total PnL for the week: +1.85% Good trades, Tom | FINEIGHT
AMEX:SPY
by Fineight
Gild Bullish trend-line PlayGilead Sciences , Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. Entry $77.50 area Target $2 trailing stoploss I been trading this stock for over a year now and once it form it's base, it usually hold itself very well in it's pattern. we could've easily scalped this stock multiple time this month for easy gain if you just buy the dip at the trend line with a tight stoploss.
NASDAQ:GILDLong
by WallSt007
XBI Potential What is XBi? XBI provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap as we see it. This highly efficient fund, which charges less than competing funds, has a history of beating its index due to revenue from securities lending. It has attracted a large asset base and trades with excellent volume. The fund’s alternative take on the space earns it a place on our Opportunities List. Looking like we could see a pull back here or breakout. Risk and reward is in our favor here. if it rejects, it can go to $95 area, if it breaks out, we can just stoploss for $1.
AMEX:XBI
by WallSt007
2
Reversing PAYS OFF!! - 05/01/20 RECAPHi traders, The other day I posted a reverse entry which happened to be a loser as well, but I told you it typically pays off. On Friday I got to prove it when WDC didn't react the way I planned and that got me thinking if the other direction wasn't a better idea... and it was! The Trades: 1) WDC - SHORT @38.73 - terrible fill at the break of 39, in hindsight I should've at least reduced the position right away to compensate. -0.96% 2) MRNA - LONG @49.58 - good break of a strong stock, it went some 60c in the money but then collapsed. With different risk management style it would pay off, but that's just my choice and I'm not upset at all. -0.93% 3) WDC - LONG @39.85 - and finally my reverse play that didn't deliver as much as I hoped for, but still proved to be the correct way to think about the stock. +1.2% *In my ID trades, I risk 1% of the account per trade and go for 2% (2:1 RRR ). Sometimes I adapt a little bit as you can see in the trades' description.* Total PnL for the day: -0.69% Total PnL for the week: +0.40% Good trades, Tom | FINEIGHT
AMEX:SPY
by Fineight
Weekly Rounded Top vs. +30% From the Low: look to long lower?Bullish: Every week since the low has closed green except this week. Bearish: The last week of each month have been particularly bearish since January. The overwhelming bull trend that's taken place over the past few weeks have been disorienting. My bias is now leaning neutral. I will consider the downtrend on hold if the monthly closes above the 17th of April high. Will switch bullish wiith a swiftness once issues with global oil pricing and the pandemic are resolved. Keeping an eye on the China/U.S. trade squabble. Black lines at the top/bottom are based on support/resistance levels and volume gaps. I should note that I am preferring the futures contract to chart for its longer session vs. the regular SPY chart or index. Recent oil news: Lack of available storage, due to it being so darn cheap to stock up on now, led to the dump of the front month futures contract. Oil also expires which explains why months further out are not as affected. www.bloomberg.com www.aljazeera.com www.wsj.com Recent coronavirus/COVID-19 news (only what could possibly be related to the markets' pricing): Possible vaccine, mRNA-1273, currently in human trials and stocks such as MRNA and GILD megapumped. Vaccines require time for trials/mass production, so it would be interesting to see how price would react the next time when a solid date on vaccine delivery is announced for...every country? I don't believe there's a globally accepted guideline on vaccine distribution. www.nasdaq.com time.com www.who.int Recent China/U.S. e-fight news: TBD There's a lot of articles out there without any proper coverage. Repeating old news in new publishments and talks related to the virus. The latter is important but oftentimes involves too much speculation and journalist bias.
CME_MINI:ES1!
by NeoButane